CI
BMY icon

Cambiar Investors’s Bristol-Myers Squibb BMY Stock Holding History

Cambiar Investors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.3M Sell
944,246
-38,930
-4% -$2.27M 2.65% 6
2025
Q4 		$53M Buy
983,176
+25,841
+3% +$1.24M 2.37% 11
2025
Q3 		$43.2M Sell
957,335
-61,815
-6% -$2.89M 1.96% 25
2025
Q2 		$47.2M Buy
1,019,150
+7,216
+0.7% +$354K 1.98% 17
2025
Q1 		$61.7M Sell
1,011,934
-27,465
-3% -$1.6M 2.62% 4
2024
Q4 		$58.8M Buy
1,039,399
+57,814
+6% +$3.23M 2.33% 8
2024
Q3 		$50.8M Buy
981,585
+195,861
+25% +$9.19M 1.95% 19
2024
Q2 		$32.6M Buy
785,724
+17,582
+2% +$787K 1.28% 35
2024
Q1 		$41.7M Sell
768,142
-38,670
-5% -$1.97M 1.55% 25
2023
Q4 		$41.4M Buy
806,812
+68,299
+9% +$3.59M 1.63% 24
2023
Q3 		$42.9M Buy
738,513
+99,262
+16% +$6.08M 1.82% 18
2023
Q2 		$40.9M Buy
+639,251
New +$42.9M 1.73% 23
2022
Q2 		– Sell
-701,850
Closed -$51.3M – 148
2022
Q1 		$51.3M Sell
701,850
-13,855
-2% -$930K 1.93% 20
2021
Q4 		$44.6M Sell
715,705
-15,215
-2% -$893K 1.53% 29
2021
Q3 		$43.2M Sell
730,920
-627
-0.1% -$41.3K 1.48% 32
2021
Q2 		$48.9M Buy
731,547
+60,019
+9% +$3.91M 1.57% 29
2021
Q1 		$42.4M Buy
671,528
+57,516
+9% +$3.58M 1.48% 30
2020
Q4 		$38.1M Buy
614,012
+213,177
+53% +$13.1M 1.49% 28
2020
Q3 		$24.2M Buy
+400,835
New +$24.1M 1.1% 45
2018
Q3 		– Sell
-560,751
Closed -$31M – 173
2018
Q2 		$31M Buy
560,751
+784
+0.1% +$42.3K 0.52% 55
2018
Q1 		$35.4M Sell
559,967
-124,498
-18% -$8.01M 0.56% 49
2017
Q4 		$41.9M Sell
684,465
-49,425
-7% -$3.09M 0.66% 41
2017
Q3 		$46.8M Sell
733,890
-19,619
-3% -$1.15M 0.73% 34
2017
Q2 		$42M Sell
753,509
-378,937
-33% -$20.6M 0.66% 45
2017
Q1 		$61.6M Sell
1,132,446
-25,059
-2% -$1.37M 1.03% 29
2016
Q4 		$67.6M Buy
1,157,505
+733,300
+173% +$40.1M 1.16% 20
2016
Q3 		$22.9M Buy
+424,205
New +$27.2M 0.33% 77

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambiar Investors's BMY Position: Q1 2026 in Review

Cambiar Investors reduced its Bristol-Myers Squibb (BMY) stake by 4% in Q1 2026, selling an estimated $2.27M and leaving 944,246 shares worth $57.3M. The position accounts for 2.65% of the portfolio, ranked #6.

Cambiar Investors first reported a position in BMY in Q3 2016 and has held it in 27 quarters since. The position peaked at $67.6M in Q4 2016. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cambiar Investors held 944,246 shares of Bristol-Myers Squibb worth $57.3M as of Q1 2026.
  • Cambiar Investors sold 38,930 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.27M.
  • Bristol-Myers Squibb made up 2.65% of Cambiar Investors's portfolio in Q1 2026, its #6 holding.
  • Cambiar Investors first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 27 quarters since.
  • Cambiar Investors's Bristol-Myers Squibb position peaked at $67.6M in Q4 2016.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cambiar Investors's 13F filing for Q1 2026, filed 12 May 2026.